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Abstract
Aims: Randomised controlled trials (RCTs) represent the most robust source of evidence-based medicine. 
However, the generalisability of RCTs is limited by the inclusion of selected populations. We sought to 
assess the external validity of a contemporary trial including patients with ST-elevation myocardial infarc-
tion (STEMI) undergoing primary percutaneous coronary intervention (PPCI).
Methods and results: Patients presenting to Bern University Hospital during the inclusion period of the 
COMFORTABLE AMI trial were divided into three groups: RCT participants (41%), eligible not included 
(17.5%), and excluded patients (41.5%). Major adverse cardiac events (MACE) were defined as one-year 
death and myocardial infarction. RCT participants compared with RCT-eligible patients had comparable 
baseline characteristics and outcomes; however, excluded patients differed in risk and had higher rates of 
MACE (HR 3.63, 95% CI: 2.03-6.48, p<0.001), death (HR 6.23, 95% CI: 2.93-13.24, p<0,001) and defi-
nite/probable stent thrombosis (HR 3.63, 95% CI: 1.79-7.36, p<0.001). Inability to provide consent was the 
most frequent exclusion criterion and was independently associated with an increased risk for MACE (HR 
6.85, 95% CI: 3.97-11.81, p<0.001).
Conclusions: In this single-centre investigation, results from the COMFORTABLE AMI trial appeared 
applicable to a broad representation of RCT-eligible patients. However, patients excluded from the trial rep-
resented a higher-risk population with impaired clinical outcomes and a lower adherence to cardiovascular 
medication.
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Introduction
Randomised controlled trials (RCTs) represent the most robust 
source of evidence-based medicine and assume the highest level 
of support in clinical practice guidelines1. Notwithstanding this, 
RCTs include selected patient populations, and it remains uncer-
tain whether the results of these studies pertain to a broader spec-
trum of patients encountered in daily clinical routine2. While the 
assessment of specific populations under controlled conditions 
increases the internal validity, it may jeopardise the external valid-
ity of the established results3. All-comers trials aim to recruit 
a wide spectrum of patients including those at higher risk for car-
diac events, which should result in higher event rates and a more 
rapid recruitment. However, a previous single-centre report sug-
gested that, even with an all-comers design, only approximately 
half of potentially eligible patients may be enrolled2.
The COMFORTABLE AMI (Comparison of Biolimus Eluted 
From an Erodible Stent Coating With Bare Metal Stents in Acute 
ST-Elevation Myocardial Infarction; NCT00962416) trial, was 
an all-comers RCT which included 1,161 patients with acute 
ST-elevation myocardial infarction (STEMI) undergoing primary 
percutaneous coronary intervention (PPCI)4. The use of a bioli-
mus-eluting stent (BES) was associated with a significant reduc-
tion of the primary endpoint at one year with a sustained effect 
over an additional year of follow-up5. The results of this and a sec-
ond PPCI trial6 were the basis for a change of the ESC guidelines 
for myocardial revascularisation in STEMI patients (i.e., a class IA 
indication for the use of newer-generation DES)1.
The aim of the present study was to assess differences in base-
line and procedural characteristics and long-term clinical out-
comes between patients included in the COMFORTABLE AMI 
trial, patients who were eligible but not included in the trial, and 
those excluded from trial participation due to formal exclusion cri-
teria at the centre contributing the largest patient number.
Methods
STUDY DESIGN AND PATIENT POPULATIONS
Details of the design of the COMFORTABLE AMI trial have been 
published elsewhere7. This multicentre, assessor-blinded, superior-
ity RCT was performed at 11 sites in Europe and Israel between 
September 2009 and January 2011. Patients were assigned to treat-
ment with a BES (BioMatrix™; Biosensors Europe SA, Morges, 
Switzerland) or a bare metal stent (BMS) (Gazelle™; Biosensors 
Europe SA, Morges, Switzerland).
The Bern PCI Registry (NCT02241291) is a prospective regis-
try which includes all consecutive patients undergoing PCI at Bern 
University Hospital. All cardiovascular events are adjudicated by 
two independent physicians. Of note, adverse event monitoring, 
data management and event adjudication were identical between 
patients included in COMFORTABLE AMI and those included in 
the Bern PCI Registry.
All consecutive patients fulfilling the criteria of STEMI and 
undergoing PPCI at Bern University Hospital within the inclusion 
period of COMFORTABLE AMI were included in this analysis, 
and divided into three groups: a) study participants (RCT), b) eli-
gible but not included patients (eligible), and c) excluded patients 
(non-eligible). The study complied with the Declaration of 
Helsinki and was approved by the institutional ethics committee.
DATA MANAGEMENT
Data were stored in a dedicated database (Cardiobase; Clinical 
Trials Unit, and Department of Cardiology, Bern University 
Hospital, Switzerland). Complete follow-up was available for 96% 
of COMFORTABLE participants, 91.5% of eligible not included 
and 90.1% of excluded patients. COMFORTABLE AMI events 
were independently adjudicated by a blinded clinical events com-
mittee (CEC).
STUDY ENDPOINTS
Similar clinical outcome definitions were applied for 
COMFORTABLE AMI patients and the Bern PCI Registry. The pri-
mary endpoint was the composite of all-cause death and any myo-
cardial infarction at one year. Myocardial infarction was defined 
according to the extended historical definition8. Other endpoints fol-
lowed the definitions of the Academic Research Consortium9.
STATISTICAL ANALYSIS
For the purposes of the present study, data from all patients undergo-
ing PPCI for STEMI treated in our institution during the time period 
of the COMFORTABLE AMI trial were analysed. Continuous vari-
ables are expressed as means±standard deviation or medians with 
interquartile ranges. P-values were derived using t-tests in the for-
mer and Mann-Whitney U tests in the latter. Categorical data are 
expressed as frequencies and percentages and are compared using 
the χ2 and Fisher’s exact tests. For nested variables in lesion-level 
data, p-values from general and generalised mixed models were used. 
Life-table estimates for events were calculated per group, and we 
used Cox regressions for comparisons. We report hazard ratios (HR) 
with 95% confidence intervals. In case of zero events, we reported 
continuity corrected risk ratios (RR) with 95% confidence intervals 
and Fisher’s test p-values. Logistic regression was used for the iden-
tification of risk factors. All p-values shown are from two-sided tests, 
and the level of statistical significance was set at 0.05. Analyses were 
performed using Stata 12 (StataCorp LP, College Station, TX, USA).
Results
During the time period for inclusion of the COMFORTABLE AMI 
trial, 608 patients underwent PPCI for STEMI at Bern University 
Hospital. One patient declined participation in the registry. Out of 
607 patients, 252 (41.5%) did not meet eligibility criteria for the 
trial; 106 (17.5%) were eligible not included patients; 249 (41%) 
were included in the trial.
BASELINE CHARACTERISTICS
Baseline characteristics are summarised in Table 1. With the 
exception of fewer male patients and more patients presenting 
with Killip III class in the eligible compared to the RCT group, 
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External validity of the COMFORTABLE trial
no differences in baseline characteristics were noted. Compared 
with RCT participants, non-eligible patients were older, more fre-
quently had a history of previous MI, PCI, gastrointestinal bleed-
ing, previous malignancy, and more often suffered from chronic 
obstructive lung disease and anaemia.
PROCEDURAL CHARACTERISTICS
Procedural characteristics are summarised in Table 2. We observed 
a gradient in the number of lesions treated per patient, with the 
highest number of lesions treated in the non-eligible group. The 
need for haemodynamic support was not different between RCT 
participants and eligible patients, but was more frequent in the 
non-eligible patients; similarly, a lower LVEF was recorded in the 
non-eligible group.
CARDIOVASCULAR MEDICATIONS
Medication use is summarised in Table 3. We observed differ-
ences in antiplatelet agents used for loading, with more frequent 
Table 1. Baseline characteristics.
RCT participants
N=249
Eligible patients (EP)
N=106
Non-eligible patients 
(NEP) N=252
p-value EP 
vs. RCT
p-value NEP 
vs. RCT
Age (years) n=249, 60.1±12.0 n=106, 61.4±13.4 n=252, 67.6±13.7 0.36 <0.001
Male gender n=249, 211 (84.7%) n=106, 80 (75.5%) n=252, 184 (73.0%) 0.05 0.001
Risk factors
Body mass index (kg/m2) n=242, 27.2±4.0 n=97, 27.2±4.6 n=210, 27.0±4.8 0.96 0.78
Current smoking n=248, 124 (50.0%) n=105, 51 (48.6%) n=237, 78 (32.9%) 0.82 <0.001
Hyperlipidaemia n=247, 116 (47.0%) n=106, 47 (44.3%) n=240, 113 (47.1%) 0.73 1.00
Hypertension n=249, 122 (49.0%) n=106, 60 (56.6%) n=240, 139 (57.9%) 0.20 0.06
Diabetes mellitus n=249, 35 (14.1%) n=106, 16 (15.1%) n=241, 48 (19.9%) 0.87 0.09
Cardiovascular history
Previous MI n=249, 10 (4.0%) n=106, 7 (6.6%) n=241, 42 (17.4%) 0.29 <0.001
Previous PCI n=249, 13 (5.2%) n=106, 10 (9.4%) n=241, 45 (18.7%) 0.16 <0.001
Previous CABG n=249, 6 (2.4%) n=106, 4 (3.8%) n=242, 12 (5.0%) 0.49 0.15
History of cerebrovascular accident 
(Stroke/TIA) n=249, 2 (0.8%) n=106, 2 (1.9%) n=241, 8 (3.3%) 0.59 0.06
Comorbidities
Renal failure (GFR <60 mL/min/1.73 m2) n=242, 17 (7.0%) n=83, 10 (12.0%) n=192, 54 (28.1%) 0.17 <0.001
Chronic obstructive lung disease n=249, 2 (0.8%) n=106, 3 (2.8%) n=241, 11 (4.6%) 0.16 0.01
History of gastrointestinal bleeding n=249, 3 (1.2%) n=106, 1 (0.9%) n=241, 13 (5.4%) 1.00 0.01
History of malignancy n=249, 8 (3.2%) n=106, 3 (2.8%) n=241, 20 (8.3%) 1.00 0.02
Anaemia n=243, 36 (14.8%) n=87, 13 (14.9%) n=204, 50 (24.5%) 1.00 0.01
Time frames
Symptom onset to balloon inflation (min) n=249, 274 (178; 487) n=79, 269 (188; 493) n=137, 286 (181; 1,143) 0.99 0.04
Symptom onset categories (hours) n=249 n=79 n=188 0.49 <0.001
0-6 hrs 157 (63.1%) 51 (64.6%) 73 (38.8%) 0.89 <0.001
7-12 hrs 57 (22.9%) 15 (19.0%) 23 (12.2%) 0.53 0.01
13-24 hrs 31 (12.4%) 13 (16.5%) 16 (8.5%) 0.35 0.21
>24 hrs 4 (1.6%) 0 (0.0%) 76 (40.4%) 0.58 <0.001
Hospital admission to balloon inflation 
(min) n=249, 40 (31; 59) n=78, 40 (30; 91) n=172, 67 (37; 118) 0.25 <0.001
Treatment during off-hoursa n=249, 107 (43.0%) n=91, 49 (53.8%) n=198, 99 (50.0%) 0.09 0.15
Killip class n=249 n=105 n=252 0.002 <0.001
I 214 (85.9%) 82 (78.1%) 157 (62.3%) 0.08 <0.001
II 27 (10.8%) 15 (14.3%) 35 (13.9%) 0.37 0.34
III 1 (0.4%) 7 (6.7%) 14 (5.6%) 0.001 0.001
IV 7 (2.8%) 1 (1.0%) 46 (18.3%) 0.45 <0.001
Data are expressed as counts (%, p-values from Fisher’s tests or χ2 tests) or means±SD (p-values from t-tests) or medians (25%-75% interquartile 
range, p-values from Mann-Whitney U tests). GFR: estimated glomerular filtration rate using Modification of Diet in Renal Disease (MDRD) formula. 
Anaemia is defined as men <130 Hb g/L, women <120 Hb g/L. aDefined as guiding catheter inserted between 8 pm and 8 am, and at weekends.
1138
EuroIntervention 2
0
16
;1
2
:113
5
-114
3
use of clopidogrel alone in eligible and non-eligible, and of clopi-
dogrel and subsequent prasugrel loading in RCT participants10. In 
a dedicated analysis for DAPT adherence at one year (Figure 1), 
excluding patients with reasons which were expected to interfere 
(e.g., use of coumadin), we observed a remaining risk increase for 
DAPT cessation in patients not enrolled in the study.
IN-HOSPITAL AND ONE-YEAR OUTCOMES
We observed no differences between RCT participants and elig-
ible patients for any cardiovascular endpoints at both time points 
(Table 4). At discharge, non-eligible patients were associated with 
a higher risk of MACE compared with RCT participants (HR 2.63, 
95% CI: 1.57-4.41, p<0.001), which was mainly driven by dif-
ferences in the rate of all-cause death (HR 2.98, 95% CI: 1.65-
5.38, p<0.001) (Figure 2A). Results at one year were consistent 
(HR 3.63, 95% CI: 2.03-6.48, p<0.001), driven by the higher 
risk of all-cause death (HR 6.23, 95% CI: 2.93-13.24, p<0.001). 
A landmark analysis at 30 days revealed no interaction by time 
(Figure 2B). Non-eligible patients were not associated with an 
increased risk of bleeding as assessed using the BARC, TIMI and 
GUSTO classifications.
Table 2. Angiographic and procedural characteristics.
RCT participants
N=249
Eligible patients (EP)
N=106
Non-eligible patients 
(NEP) N=252
p-value EP 
vs. RCT
p-value NEP 
vs. RCT
Infarct-related artery
Left anterior descending artery 108 (43.4%) 43 (40.6%) 117 (46.4%) 0.64 0.53
Lesions per patient n=249, 1.4±0.7 n=106, 1.6±0.8 n=252, 1.8±1.1 0.02 <0.001
Multivessel treatment n=249, 36 (14.5%) n=106, 13 (12.3%) n=252, 57 (22.6%) 0.74 0.02
Haemodynamic support
IABP n=249, 8 (3.2%) n=106, 0 (0.0%) n=252, 21 (8.3%) 0.11 0.02
Percutaneous left ventricular assist device n=249, 0 (0.0%) n=83, 0 (0.0%) n=194, 5 (2.6%) 0.02
Vasopressors n=249, 8 (3.2%) n=106, 4 (3.8%) n=252, 44 (17.5%) 0.76 <0.001
Left ventricular function n=246, 47.2±10.2 n=101, 47.5±11.2 n=239, 42.3±11.9 0.86 <0.001
No. of treated lesions N=343 N=167 N=446
Lesion type
Restenosis n=343, 2 (0.6%) n=167, 1 (0.6%) n=446, 36 (8.1%) 0.98 0.001
Baseline TIMI flow n=342 n=160 n=435 0.02 0.20
0 or 1 188 (55.0%) 76 (47.5%) 209 (48.0%)
2 50 (14.6%) 40 (25.0%) 88 (20.2%)
3 104 (30.4%) 44 (27.5%) 138 (31.7%)
Thrombus aspiration n=150, 122 (81.3%) n=53, 29 (54.7%) n=115, 68 (59.1%) 0.05 0.02
TIMI flow after procedure n=343 n=161 n=439 0.51 0.25
0 or 1 3 (0.9%) 2 (1.2%) 11 (2.5%)
2 18 (5.2%) 4 (2.5%) 27 (6.2%)
3 322 (93.9%) 155 (96.3%) 401 (91.3%)
Stent type
Any newer-generation DES n=332, 174 (52.4%) n=146, 130 (89.0%) n=378, 276 (73.0%) <0.001 <0.001
Total stent length (mm) n=332, 23.98±12.51 n=146, 25.66±13.90 n=377, 23.59±11.98 0.22 0.77
Mean stent diameter (mm) n=332, 3.11±0.46 n=146, 2.99±0.46 n=377, 2.98±0.51 0.03 0.002
Data are expressed as counts (%) or means±SD. P-values from Fisher’s tests and t-tests, respectively, for the patient-level data (upper part of the Table). 
P-values from general and generalised mixed models accounting for lesions nested within patients for the lesion-level data (lower part of the Table).
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Figure 1. Dual antiplatelet therapy (DAPT) cessation within one 
year. First stop recorded as time-to-DAPT cessation. Patients 
meeting the following criteria were excluded from this analysis: 
in-hospital death (31), without DAPT at discharge (19), lost at 
follow-up (45), oral anticoagulation at discharge (13), history of 
bleeding diathesis (7), and planned surgery with DAPT interruption 
(11). Blue: study participants (SP); green: eligible not included 
patients (EP); red: non-eligible patients (NEP); USD: number of 
patients with uncertain stop dates.
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PREDICTORS OF EVENTS AMONG RCT NON-ELIGIBLE PATIENTS
Exclusion criteria that were independently associated with a sig-
nificantly higher rate of MACE were inability to provide informed 
consent (HR 6.85, 95% CI: 3.97-11.81, p<0.001), increased base-
line bleeding risk (HR 3.59, 95% CI: 1.66-7.77, p=0.001), and 
mechanical complications of acute MI (HR 8.73, 95% CI: 2.05-
37.07, p=0.003) (Figure 3).
Discussion
The principal findings of this single-centre investigation of the 
external validity of a contemporaneous PPCI trial are as follows:
1.  In-hospital and one-year cardiovascular event rates were compa-
rable between STEMI patients enrolled in the COMFORTABLE 
AMI trial and RCT-eligible but not included patients, attesting 
to the external validity of the results of the original trial.
Table 3. Medication use during the index procedure, at discharge and at one-year follow-up.
RCT participants
N=249
Eligible patients (EP)
N=106
Non-eligible patients 
(NEP) N=252
p-value EP 
vs. RCT
p-value NEP 
vs. RCT
During index PCI
P2Y12 inhibitors n=249 n=106 n=252 <0.001 <0.001
Only clopidogrel loading 35 (14.1%) 46 (43.4%) 154 (61.1%) <0.001 <0.001
Only prasugrel loading 35 (14.1%) 12 (11.3%) 33 (13.1%) 0.61 0.80
Clopidogrel and prasugrel loading 179 (71.9%) 44 (41.5%) 47 (18.7%) <0.001 <0.001
At discharge
Aspirin, n (%) n=245, 245 (100.0%) n=105, 105 (100.0%) n=228, 217 (95.2%) <0.001
Clopidogrel, n (%) n=245, 27 (11.0%) n=105, 40 (38.1%) n=228, 130 (57.0%) <0.001 <0.001
Prasugrel, n (%) n=245, 218 (89.0%) n=105, 64 (61.0%) n=228, 87 (38.2%) <0.001 <0.001
Any DAPT, n (%) n=245, 245 (100.0%) n=105, 104 (99.0%) n=228, 208 (91.2%) 0.30 <0.001
Oral anticoagulation, n (%) n=245, 1 (0.4%) n=104, 0 (0.0%) n=228, 16 (7.0%) 1.00 <0.001
Statin, n (%) n=245, 244 (99.6%) n=104, 101 (97.1%) n=228, 212 (93.0%) 0.08 <0.001
At one year
Aspirin, n (%) n=231, 229 (99.1%) n=90, 88 (97.8%) n=175, 163 (93.1%) 0.31 0.001
Clopidogrel, n (%) n=231, 26 (11.3%) n=91, 32 (35.2%) n=175, 86 (49.1%) <0.001 <0.001
Prasugrel, n (%) n=231, 192 (83.1%) n=90, 48 (53.3%) n=175, 37 (21.1%) <0.001 <0.001
Any DAPT, n (%) n=231, 216 (93.5%) n=90, 77 (85.6%) n=175, 115 (65.7%) 0.03 <0.001
Oral anticoagulation, n (%) n=229, 9 (3.9%) n=90, 1 (1.1%) n=174, 15 (8.6%) 0.29 0.06
Statin, n (%) n=229, 221 (96.5%) n=90, 83 (92.2%) n=173, 159 (91.9%) 0.14 0.05
Data are expressed as counts (%, p-values from Fisher’s tests). Loading includes patients who were already on a daily dosage of the indicated APT.
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Figure 2. Kaplan-Meier curves and landmark analysis. A) All-cause death or myocardial infarction at one year. B) Landmark analysis at 30 
days and between 30 days and one year for all-cause death or myocardial infarction. Blue: study participants, green: eligible not included 
patients, red: non-eligible patients.
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2. Baseline characteristics were comparable among RCT partici-
pants and RCT-eligible patients, whereas RCT-ineligible patients 
carried a higher burden of comorbidities and procedural factors.
3. STEMI patients fulfilling exclusion criteria carried a higher car-
diovascular mortality, without difference in the risk of myocar-
dial infarction or repeat revascularisation.
4. RCT participants underwent more structured invasive and phar-
macological interventions and showed an increased adherence 
to recommended cardiovascular medication including DAPT 
when compared with non-trial participants.
5. Inability to provide informed consent was the most frequent 
exclusion criterion and was associated with a seven times 
higher risk of death or myocardial infarction.
External validity is defined as the reasonable applicability of the 
results of a study to a definable group of patients in a particu-
lar clinical setting in routine clinical practice3. Rothwell et al 
proposed six criteria for the assessment of external validity3. We 
previously reported details on the selection of patients, outcome 
measures, follow-up quality and adverse effects of the treatment4. 
The present analysis focuses on the characteristics of randomised 
versus non-randomised patients and differences between the trial 
protocol and routine clinical practice at the centre contributing the 
largest patient number of the trial.
All patients included in this analysis were screened by a dedi-
cated physician (24 hours/7 days) for enrolment into the PPCI 
trial. Pre-specified exclusion criteria were met by 41% of patients 
Exclusion criteria
Inability to provide informed consent
Late presentation >24 hours
Increased risk of bleeding
STEMI secondary to stent thrombosis
Angiographic exclusion
Planned surgery with DAPT disc.
Non-cardiac life expectancy less than 1 yr
Allergy
Mechanical complications of acute MI
Participation in another trial
0 5 10 15 20 25 30 35 40
% of 252 non-eligible patients
Number of
non-eligible
(%)
Events in 
non-eligible
(%)
Events in 
eligiblea
(%) Hazard ratio (95% CI)125 25 5   1   2   4   8
87 (35.5%)
63 (25.7%)
44 (18.0%)
23 (9.4%)
19 (7.8%)
16 (6.5%)
9 (3.7%)
7 (2.9%)
5 (2.0%)
5 (2.0%)
30 (36.5)
6 (10.2)
9 (21.6)
1 (4.8)
2 (12.5)
1 (6.7)
2 (23.8)
1 (14.3)
2 (40.0)
0 (0.0)
23 (6.6)
23 (6.6)
23 (6.6)
23 (6.6)
23 (6.6)
23 (6.6)
23 (6.6)
23 (6.6)
23 (6.6)
23 (6.6)
HR (95% CI) p-value
6.85 (3.97-11.81) <0.001
1.57 (0.64-3.87) 0.32
3.59 (1.66-7.77) 0.001
0.69 (0.09-5.11) 0.72
1.82 (0.43-7.72) 0.42
0.99 (0.13-7.35) 0.99
4.04 (0.95-17.15) 0.058
2.09 (0.28-15.48) 0.47
8.73 (2.05-37.07) 0.003
2.47 (0.40-15.4O)b 1.00
Figure 3. Effect of individual exclusion criteria on all-cause death and myocardial infarction at one year. aEvents in RCT participants and 
RCT-eligible patients. bContinuity corrected risk ratio (95% CI) with Fisher’s exact test.
Table 4. Clinical outcomes at discharge and at one-year follow-up.
RCT 
participants
N= 49
Eligible 
patients (EP)
N=106
Non-eligible 
patients (NEP)
N=252
EP vs. RCT NEP vs. RCT
HR or RR (95% CI) p-value HR or RR (95% CI) p-value
Death or MI (any) 15 (6.1) 8 (7.9) 48 (20.2) 1.31 (0.55-3.09) 0.54 3.63 (2.03-6.48) <0.001
Cardiac death, TV-MI, TLR (DOCE) 18 (7.3) 7 (7.0) 45 (19.1) 0.95 (0.40-2.28) 0.92 2.84 (1.65-4.91) <0.001
Death, MI, any revasc (POCE) 22 (9.0) 13 (13.0) 59 (25.0) 1.47 (0.74-2.92) 0.27 3.11 (1.90-5.07) <0.001
Death 8 (3.2) 5 (5.0) 44 (18.5) 1.52 (0.50-4.64) 0.46 6.23 (2.93-13.24) <0.001
Cardiac death 8 (3.2) 4 (4.0) 38 (15.9) 1.21 (0.36-4.02) 0.76 5.31 (2.48-11.39) <0.001
Myocardial infarction 8 (3.3) 4 (4.0) 4 (2.0) 1.24 (0.37-4.13) 0.72 0.59 (0.18-1.96) 0.39
Revascularisation (any) 17 (7.1) 9 (9.2) 15 (7.7) 1.35 (0.60-3.02) 0.47 1.07 (0.53-2.14) 0.85
Revascularisation (TLR) 13 (5.4) 4 (4.0) 7 (3.7) 0.77 (0.25-2.37) 0.65 0.65 (0.26-1.62) 0.35
Revascularisation (TVR) 13 (5.4) 5 (5.1) 9 (4.7) 0.96 (0.34-2.71) 0.95 0.84 (0.36-1.96) 0.68
Stent thrombosis (definite) 5 (2.0) 3 (3.0) 2 (0.9) 1.47 (0.35-6.15) 0.60 0.47 (0.09-2.40) 0.36
BARC 
bleeding
Bleeding BARC (3abc) 9 (3.7) 1 (0.9) 7 (3.2) 0.27 (0.03-2.10) 0.21 0.85 (0.32-2.28) 0.74
Bleeding BARC (4) 0 (0.0) 0 (0.0) 0 (0.0)
Bleeding BARC (5ab) 1 (0.4) 0 (0.0) 2 (0.9) 0.78 (0.03-18.99) 100 2.16 (0.20-23.84) 0.53
Depicted are number of first events (% from life-table estimates) per group, and the results of Cox regressions comparing the eligible not included 
patients vs. study participants, and the not eligible patients vs. study participants, hazard ratios (HR) with 95% confidence intervals, and p-values. 
Continuity corrected risk ratios (RR) with 95% confidence intervals, and Fisher’s test p-values reported in case of zero events.
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and an additional 18% either declined participation or were not 
included, as factors were present that precluded randomisation 
despite not being predefined as exclusion criteria. In addition, fac-
tors unrelated to the patients may have prevented timely consent 
and randomisation, such as treatment of multiple STEMI patients 
at the same time, unavailability of both stents, or fatigue of the 
operator during night hours. Overall, two thirds of eligible patients 
were actually included in the RCT. A comparable inclusion rate 
(60%) was reported in the Thrombus Aspiration in ST-Elevation 
Myocardial Infarction in Scandinavia (TASTE) trial, a contempora-
neous all-comers RCT in STEMI patients investigating the impact 
of thrombus aspiration on mortality at 30 days11. Conversely, the 
recently published How Effective are Antithrombotic Therapies in 
Primary Percutaneous Coronary Intervention (HEAT-PPCI) trial 
was able to randomise 95% of patients scheduled for an emer-
gent angiography12. The high inclusion rate was largely the con-
sequence of a policy of delayed consent, preserving the inclusion 
of critically ill patients who were unable to provide consent before 
the procedure.
Patients who were not eligible for RCT inclusion showed a sig-
nificantly higher baseline risk profile in this analysis. It is notewor-
thy that one third was unable to provide informed consent owing 
to a critical condition including a sixfold more frequent presenta-
tion with Killip class IV compared with trial participants, which in 
turn is one of the strongest predictors of mortality among STEMI 
patients13. As a result, the present study indicates that in-hospital 
and one-year outcomes are considerably impaired among RCT-
ineligible patients. Similar findings have been reported in a recent 
sub-analysis of the Harmonizing Outcomes with Revascularization 
and Stents in Acute Myocardial Infarction (HORIZONS-AMI) 
trial14. Exclusion due to late presentation (>24 hours) was not 
infrequent. Although PPCI may be considered for this subset of 
patients, several factors (i.e., residual ischaemia, intermittent coro-
nary flow, or collateral flow) may influence the benefits expected 
from the intervention, preventing to some degree the comparabil-
ity with patients receiving early invasive treatment15.
Eligible not included patients have shown a higher baseline 
risk when compared to included patients in previous studies, 
denoting the impact of clinical selection beyond eligibility crite-
ria16. We identified conditions that may have influenced the deci-
sion to enrol the patient such as multiple comorbidities, doubtful 
future adherence (i.e., drug addiction, psychiatric disorders), 
among others, in the eligible not included group. Both the benefi-
cial impact of experimental interventions or therapies and a closer 
medical attention have been suggested as reasons for improved 
outcomes in RCT participants16,17. Indeed, a more aggressive anti-
platelet treatment was observed in RCT participants (i.e., more 
frequent use of glycoprotein IIb/IIIa inhibitors and prasugrel), as 
well as a higher frequency of patients on DAPT throughout one 
year. Specifically, we observed that real-life STEMI patients tend 
to stop DAPT earlier than initially prescribed, a finding suggest-
ing that adherence to DAPT requires monitoring by the treating 
GP or cardiologist.
Despite these differences, a similar baseline risk and comparable 
cardiovascular event rates were observed in this all-comers RCT 
among RCT participants and eligible not included patients, attest-
ing to the high degree of external validity. Considering the impact 
of COMFORTABLE AMI (together with EXAMINATION) on 
the current revascularisation guidelines, fulfilling the requirements 
for external validity is of great importance. In agreement with 
our data, the TWENTE all-comers trial confirmed similar clini-
cal outcomes in study patients and eligible not included NSTEMI 
patients17.
While there is no evidence against the applicability of the 
results in non-eligible patients, or a pathophysiological basis to 
support such conclusions18, it seems prudent to rely on RCTs and 
clinical guidelines for decision making. Notwithstanding this, the 
increasing complexity of patients undergoing interventional pro-
cedures today often compels us to an individualised approach. 
The effect of drugs and devices may differ in subsets of patients 
largely excluded from RCTs. To improve the representation of 
critically ill patients within RCTs, postponing the informed con-
sent to a time point after the random treatment allocation may be 
the only solution, something that certainly requires intense ethical 
consideration.
Limitations
Our results have to be interpreted in view of the following limita-
tions. First, despite the multicentre nature of the COMFORTABLE 
AMI trial, we performed our analysis based on data from a single 
centre that contributed the largest number of patients. The avail-
ability of a prospective registry and the unified criteria for defi-
nition of events at Bern University Hospital have favoured this 
approach, and this strategy has been utilised in previous stud-
ies2,14. Second, reasons for eligibility beyond exclusion criteria 
were not prospectively recorded, and we were not able to pro-
vide the reasons that prevented randomisation for the majority of 
eligible, non-randomised patients. Third, the use of drug-eluting 
stents was underrepresented in the RCT population; however, 
limitations inherent to the sample size prevented stratification by 
stent type for the purpose of comparisons. Fourth, longer follow-
up may identify differences that cannot be detected in a one-year 
period. However, Kaplan-Meier curves suggest that the findings of 
the current analysis may prevail over time. Finally, as a post hoc 
analysis, the present study should be considered exploratory and 
hypothesis-generating.
Conclusions
Contemporaneous RCTs in patients presenting with ST-elevation 
myocardial infarction, with less stringent exclusion criteria, pro-
vide an appropriate representation of eligible not included patients 
if conducted using an all-comers approach. Excluded patients rep-
resent a higher-risk population, and caution should be applied 
when extrapolating results from RCTs to this subset of patients. 
Inability to provide written consent is the most frequent reason for 
exclusion and associated with a substantially increased mortality.
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Impact on daily practice
Results from the COMFORTABLE AMI trial in patients under-
going primary percutaneous coronary intervention for STEMI 
may be generalised to populations fulfilling trial-specific eli-
gibility criteria. However, patients excluded exhibited worse 
baseline conditions, higher event rates, and lower adherence 
to cardiovascular medications. Admission in a critical condi-
tion, not allowing the patient to provide informed consent for 
a randomised trial, and an increased bleeding risk were inde-
pendently associated with a higher risk of clinical events at one 
year, denoting the importance of close monitoring for these 
patients.
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